If second-generation tau PET tracers continuously prove their value, they have the potential to replace amyloid and FDG-PET in some scenarios in clinical practice (e.g., in the different types of tauopathies), providing “one-stop-shop” studies of pathology and disease staging at the same time. The gene discussed is MAPT; the disease is tauopathy.